

Clinical Trial Protocol

Iranian Registry of Clinical Trials

14 Jul 2026

Comparison of the effect of dietary approaches to stop hypertension (DASH) diet with regular hypocaloric diet on cardiometabolic parameters, oxidative stress and inflammatory markers, hepatic enzymes, and fatty liver severity in patients with non-alcoholic fatty liver disease

Protocol summary

Study aim

Comparison of the effect of dietary approaches to stop hypertension (DASH) diet with regular hypocaloric diet on cardiometabolic parameters, oxidative stress and inflammatory markers, hepatic enzymes, and fatty liver severity in patients with non-alcoholic fatty liver disease

Design

The clinical trial has a control group, with 3 parallel groups (40 in each group), single blinded, randomized by random number table method

Settings and conduct

The number of 120 eligible patients for the study (40 in each group) will be selected. Then the subjects will be divided into three groups by permuted block randomization. The three groups include: dietary approaches to stop hypertension (DASH) diet, Hypocaloric diet, and DASH + Hypocaloric diet. The diet will be written to each individual. In this way, the required energy will be calculated based on Harris Benedict formula. In Group 1 the required energy will be determined and without deduction of energy units of each food groups will be determined based on the DASH diet. In Group 2 and 3 the rate of 500 kcal will be deducted, then units of each food groups will be determined based on a regular diet in group 2 and DASH diet in group 3. After 3 months of intervention, all groups will be compared for their changes in cardiometabolic parameters, oxidative stress, inflammatory markers, hepatic enzymes, and fatty liver severity.

Participants/Inclusion and exclusion criteria

Inclusion criteria: NAFLD patients should have BMI more than 25 exclusion criteria: Patients with dire diseases, Pregnancy, Alcohol consumption

Intervention groups

The subjects divide into 3 groups, Group 1: receiving dietary approaches to stop hypertension (DASH) diet,

Group 2: receiving hypocaloric diet, Group 3: receiving hypocaloric DASH diet

Main outcome variables

Cardiometabolic parameters; Oxidative stress and inflammatory markers; Hepatic enzymes; Fatty liver severity

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20121029011307N2**

Registration date: **2020-03-03, 1398/12/13**

Registration timing: **retrospective**

Last update: **2020-03-03, 1398/12/13**

Update count: **0**

Registration date

2020-03-03, 1398/12/13

Registrant information

Name

Zeynab Hatami Zargaran

Name of organization / entity

Health and Nutrition School, Shiraz University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 71 1725 1002

Email address

hatamiz@sums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-06-22, 1398/04/01

Expected recruitment end date

2019-07-23, 1398/05/01

Actual recruitment start date

2019-07-24, 1398/05/02

Actual recruitment end date

2019-08-24, 1398/06/02

Trial completion date

2019-12-31, 1398/10/10

Scientific title

Comparison of the effect of dietary approaches to stop hypertension (DASH) diet with regular hypocaloric diet on cardiometabolic parameters, oxidative stress and inflammatory markers, hepatic enzymes, and fatty liver severity in patients with non-alcoholic fatty liver disease

Public title

Comparison of the effect of dietary approaches to stop hypertension (DASH) diet to improve non-alcoholic fatty liver disease

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Having a non alcoholic fatty liver disease (NAFLD) to diagnose a doctor (using Ultra Ultrasound) willing to participate in the study

Exclusion criteria:

Patients with cardiovascular disease, liver disease (cirrhosis, alcoholic liver disease, viral hepatitis, autoimmune hepatitis, primary bile cirrhosis, bile obstruction, liver damage induced by hereditary hemochromatosis drugs, sclerosis, and α -antitrypsin deficiency), other dire diseases Such as cancer, kidney failure and... Celiac Pregnancy, lactation Taking medications that cause fatty liver (methotrexate, tamoxifen, Oalprowat, etc.) Taking blood lipid-lowering drugs Malnutrition Having certain diets like vegetarian and raw veganism Alcohol consumption

AgeFrom **20 years** old to **60 years** old**Gender**

Both

Phase

N/A

Groups that have been masked

- Participant

Sample sizeTarget sample size: **120**Actual sample size reached: **120****Randomization (investigator's opinion)**

Randomized

Randomization description

Permuted block randomization: First, the list of participants was provided according to their referral. Then all possible sequences that can be written with three groups, were written on paper (for 3 groups 6 sequences can be written). Then one of the numbers from 1 to 6 was considered for each sequence, for

example for the ABC sequence 1 and for the ACB sequence 2 and as such, one of the numbers 3 to 6 was considered for the other 4 sequences. Then, using random number table, the random numbers were selected from one point to the left or right. Wherever the random number was 1 to 6, the corresponding sequence was recorded on the paper, and wherever the numbers were 0 or 7, 8, 9, the next number that was between 1 to 6 was considered. This method continued until groups for the total number of participants were determined. Then, the names of subjects on the list were allocated to the specific groups according to the sequence of groups which had been determined by the above mentioned procedure.

Blinding (investigator's opinion)

Single blinded

Blinding description

Participants are unaware of the differences in the incoming regimes.

Placebo

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Shiraz University of Medical Sciences

Street address

Reyhaneh building, 8/6 Alley, Southern Hemmat Avenue

City

Shiraz

Province

Fars

Postal code

7188776461

Approval date

2019-04-22, 1398/02/02

Ethics committee reference number

IR.SUMS.REC.1398.314

Health conditions studied**1****Description of health condition studied**

Non-alcoholic fatty liver disease

ICD-10 code

K76.0

ICD-10 code description

Fatty (change of) liver, not elsewhere classified

Primary outcomes

1

Description

Fatty liver severity

Timepoint

At the beginning of the study (before intervention) and three months after the beginning of the intervention

Method of measurement

Using Ultrasound

Secondary outcomes

1

Description

Isoprostane 8

Timepoint

At the beginning of the study (before intervention) and three months after the beginning of the intervention

Method of measurement

Enzyme-linked immunosorbent kit

2

Description

Interleukin 6

Timepoint

At the beginning of the study (before intervention) and three months after the beginning of the intervention

Method of measurement

Enzyme-linked immunosorbent kit

3

Description

C-Reactive Protein

Timepoint

At the beginning of the study (before intervention) and three months after the beginning of the intervention

Method of measurement

Enzyme-linked immunosorbent kit

4

Description

Aspartate aminotransferase

Timepoint

At the beginning of the study (before intervention) and three months after the beginning of the intervention

Method of measurement

Calorimetry method

Intervention groups

1

Description

Intervention group 1: Receiving dietary approaches to stop hypertension diet(DASH). In this group, the required energy of each person will be determined based

on Harris Benedict formula and without deduction of energy, units of each food groups will be determined based on DASH diet. DASH diet is rich in fruits, vegetables, whole grains, low-fat dairy foods and is limited in saturated fatty acids, total fat and cholesterol, refined cereals and sugar sweetened drinks with an overall 2400 mg per day sodium intake.

Category

Treatment - Other

2

Description

Intervention group 2: Receiving hypocaloric diet. In this group, the required energy of each person will be determined based on Harris Benedict formula, the rate of 500 kcal will be deducted then units of each food groups will be determined based on a regular diet.

Category

Treatment - Other

3

Description

Control group: Receiving dietary approaches to stop hypertension diet (DASH) hypocaloric diet. In this group, the required energy of each person will be determined based on Harris Benedict formula, the rate of 500 kcal will be deducted then units of each food groups will be determined based on DASH diet.

Category

Treatment - Other

Recruitment centers

1

Recruitment center

Name of recruitment center

Emam Reza clinic

Full name of responsible person

Zeinab Hatami Zargaran

Street address

Reyhaneh building, 8/6 Alley, Southern Hemmat Avenue

City

Shiraz

Province

Fars

Postal code

7188776461

Phone

+98 71 3632 1066

Email

hatamiz@sums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Dr.Yunes Qasemi

Street address

Reyhaneh building, 8/6 Alley, Southern Hemmat Avenue

City

Shiraz

Province

Fars

Postal code

7188776461

Phone

+98 71 3632 1066

Email

hatamiz@sums.ac.ir

Grant name

Grant code / Reference number

SG-97-37

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shiraz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Zeinab Hatami Zargaran

Position

PhD student

Latest degree

Master

Other areas of specialty/work

Nutrition

Street address

Reyhaneh building, 8/6 Alley, Southern Hemmat Avenue

City

Shiraz

Province

Fars

Postal code

7188776461

Phone

+98 71 3632 1066

Email

z_hatami_65@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Zeinab Hatami Zargaran

Position

PhD student

Latest degree

Master

Other areas of specialty/work

Nutrition

Street address

Reyhaneh building, 8/6 Alley, Southern Hemmat Avenue

City

Shiraz

Province

Fars

Postal code

7188776461

Phone

+98 71 3632 1066

Email

z_hatami_65@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Zeinab Hatami Zargaran

Position

PhD student

Latest degree

Master

Other areas of specialty/work

Nutrition

Street address

Reyhaneh building, 8/6 Alley, Southern Hemmat Avenue

City

Shiraz

Province

Fars

Postal code

7188776461

Phone

+98 71 3632 1066

Email

z_hatami_65@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to

make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available